Insider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells 16,925 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 16,925 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50. Following the completion of the transaction, the chief executive officer owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. This trade represents a 6.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Vera Therapeutics Stock Down 1.6%

Shares of NASDAQ VERA traded down $0.69 during mid-day trading on Wednesday, hitting $41.68. The company had a trading volume of 776,869 shares, compared to its average volume of 897,432. The company has a market capitalization of $2.92 billion, a PE ratio of -10.45 and a beta of 1.16. The business’s 50-day simple moving average is $46.63 and its 200 day simple moving average is $35.30. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $56.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VERA. Evercore lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Wedbush raised their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a research report on Friday, December 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $77.18.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Vera Therapeutics during the 4th quarter worth $297,000. Invesco Ltd. boosted its stake in shares of Vera Therapeutics by 193.3% during the fourth quarter. Invesco Ltd. now owns 89,851 shares of the company’s stock worth $4,550,000 after buying an additional 59,219 shares during the period. KVP Capital Advisors LP acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth about $1,656,000. XTX Topco Ltd purchased a new position in shares of Vera Therapeutics during the fourth quarter worth about $508,000. Finally, Virtus Investment Advisers LLC increased its position in Vera Therapeutics by 5.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after acquiring an additional 290 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.